参考文献 References
[1] SUNG H, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J/OL]. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209-249.
[2] LEE A W M, et al. Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective[J/OL]. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2015, 33(29): 3356-3364.
[3] DIAZ L A, BARDELLI A. Liquid Biopsies: Genotyping Circulating Tumor DNA[J/OL]. Journal of Clinical Oncology, 2014, 32(6): 579-586.
[4] AALTONEN K E, et al. Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy[J/OL]. Oncotarget, 2017, 8(28): 45544-45565.
[5] CHATURVEDI V K, et al. Cancer Nanotechnology: A New Revolution for Cancer Diagnosis and Therapy[J/OL]. Current Drug Metabolism, 2019, 20(6): 416-429.
[6] MARTINS I, et al. Liquid Biopsies: Applications for Cancer Diagnosis and Monitoring[J/OL]. Genes, 2021, 12(3): 349.
[7] IGNATIADIS M, SLEDGE G W, JEFFREY S S. Liquid biopsy enters the clinic — implementation issues and future challenges[J/OL]. Nature Reviews Clinical Oncology, 2021, 18(5): 297-312.
[8] SMERAGE J B, et al. Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500[J/OL]. Journal of Clinical Oncology, 2014, 32(31): 3483-3489.
[9] POVEDA A, et al. Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer[J/OL]. Gynecologic Oncology, 2011, 122(3): 567-572.
[10] TARTARONE A, et al. Molecular characterization and prognostic significance of circulating tumor cells in patients with non-small cell lung cancer[J/OL]. Journal of Thoracic Disease, 2017, 9(S13): S1359-S1363.
[11] COHEN S J, et al. Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer[J/OL]. Journal of Clinical Oncology, 2008, 26(19): 3213-3221.
[12] WU X L, et al. Diagnostic and Prognostic Value of Circulating Tumor Cells in Head and Neck Squamous Cell Carcinoma: a systematic review and meta-analysis[J/OL]. Scientific Reports, 2016, 6(1): 20210.
[13] LIU K, et al. Clinical significance of circulating tumor cells in patients with locally advanced head and neck squamous cell carcinoma[J/OL]. Oncology Reports, 2020[2023-09-23].http://www.spandidos-publications.com/10.3892/or.2020.7536.
[14] LI F, et al. Circulating tumor cells in the blood of poorly differentiated nasal squamous cell carcinoma patients: correlation with treatment response[J/OL]. Acta Oto-Laryngologica, 2016, 136(11): 1164-1167.
[15] VO J H, et al. Comparison of Circulating Tumour Cells and Circulating Cell-Free Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Undergoing Radiotherapy [J/OL]. Scientific Reports, 2016, 6(1): 13.
[16] ELGUI DE OLIVEIRA D, MÜLLER-COAN B G, PAGANO J S. Viral Carcinogenesis Beyond Malignant Transformation: EBV in the Progression of Human Cancers[J/OL]. Trends in Microbiology, 2016, 24(8): 649-664.
[17] XIE X Q, et al. Clinical significance of circulating tumor cells and their expression of cyclooxygenase-2 in patients with nasopharyngeal carcinoma[J/OL]. European Review for Medical and Pharmacological Sciences, 2019, 23(16): 6951-6961.
[18] YANG Z, et al. Epstein-Barr Virus-Encoded Products Promote Circulating Tumor Cell Generation: A Novel Mechanism of Nasopharyngeal Carcinoma Metastasis [J/OL]. OncoTargets and Therapy, 2020, Volume 12: 11793-11804.
[19] 董小丽, 赵恩锋. 上皮-间质型循环肿瘤细胞在卵巢癌复发转移中的作用[J]. 解放军医学杂志, 2016, 41(9): 788-791.
[20] KRISHNAMURTHY S, et al. Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer[J/OL]. Cancer Medicine, 2013, 2(2): 226-233.
[21] LI Y J, et al. The prognostic value of COX-2 expression on circulating tumor cells in nasopharyngeal carcinoma: A prospective analysis[J/OL]. Radiotherapy and Oncology, 2018, 129(2): 396-402.
[22] MISHIMA Y, et al. Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients[J/OL]. Targeted Oncology, 2017, 12(3): 341-351.
[23] NANOU A, et al. HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer[J/OL]. Breast Cancer Research, 2020, 22(1): 86.
[24] JACOT W, et al. Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial[J/OL]. Breast Cancer Research, 2019, 21(1): 121.
[25] BEIJE N, et al. Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor[J/OL]. Neoplasia, 2016, 18(11): 647-653.
[26] GRADILONE A, et al. Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization[J/OL]. Annals of Oncology, 2011, 22(1): 86-92.
[27] FORSARE C, et al. Evolution of Estrogen Receptor Status from Primary Tumors to Metastasis and Serially Collected Circulating Tumor Cells[J/OL]. International Journal of Molecular Sciences, 2020, 21(8): 2885.
[28] FRIEDLANDER T W, et al. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer: Invasive prostate cancer CTC detection[J/OL]. International Journal of Cancer, 2014, 134(10): 2284-2293.
[29] YIN C, et al. Molecular Profiling of Pooled Circulating Tumor Cells from Prostate Cancer Patients Using a Dual-Antibody-Functionalized Microfluidic Device[J/OL]. Analytical Chemistry, 2018, 90(6): 3744-3751.
[30] WEI S, et al. Effect of Vein-First vs Artery-First Surgical Technique on Circulating Tumor Cells and Survival in Patients With Non–Small Cell Lung Cancer: A Randomized Clinical Trial and Registry-Based Propensity Score Matching Analysis[J/OL]. JAMA Surgery, 2019, 154(7): e190972.
[31] KULASINGHE A, et al. The prognostic significance of circulating tumor cells in head and neck and non‐small‐cell lung cancer[J/OL]. Cancer Medicine, 2018, 7(12): 5910-5919.
[32] STRATI A, et al. Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma[J/OL]. Annals of Oncology, 2017, 28(8): 1923-1933.
[33] 辇伟奇, 于津浦, 袁响林, 等. ctDNA高通量测序临床实践专家共识（2022年版）[J]. 中国癌症防治杂志, 2022, 14(3): 240-252.
[34] TIE J, et al. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer[J/OL]. New England Journal of Medicine, 2022, 386(24): 2261-2272.
[35] XU J, et al. Evaluation of Clinical Outcomes of Icotinib in Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR -Sensitizing Variants Assessed by Circulating Tumor DNA Testing: A Phase 2 Nonrandomized Clinical Trial[J/OL]. JAMA Oncology, 2022, 8(9): 1328.
[36] TOPHAM J T, et al. Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti–Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer[J/OL]. Journal of Clinical Oncology, 2023, 41(3): 485-496.
[37] LIPSYC-SHARF M, et al. Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer[J/OL]. Journal of Clinical Oncology, 2022, 40(22): 2408-2419.
[38] MAGBANUA M J M, et al. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy[J/OL]. Cancer Cell, 2023, 41(6): 1091-1102.e4.
[39] CHEN Q Y, et al. Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort Study[J/OL]. Cancer Research and Treatment, 2018, 50(3): 861-871.
[40] ZHANG L, et al. Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy[J/OL]. Oncotarget, 2016, 7(5): 6221-6230.
[41] GUO R, et al. Proposed modifications and incorporation of plasma Epstein‐Barr virus DNA improve the TNM staging system for Epstein‐Barr virus‐related nasopharyngeal carcinoma[J/OL]. Cancer, 2019, 125(1): 79-89.
[42] LEE V H, et al. The addition of pretreatment plasma Epstein–Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification[J/OL]. International Journal of Cancer, 2019, 144(7): 1713-1722.
[43] XU C, et al. Selection and Validation of Induction Chemotherapy Beneficiaries Among Patients With T3N0, T3N1, T4N0 Nasopharyngeal Carcinoma Using Epstein-Barr Virus DNA: A Joint Analysis of Real-World and Clinical Trial Data[J/OL]. Frontiers in Oncology, 2019, 9: 1343.
[44] TAN R, et al. Clinical utility of Epstein‐Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma[J/OL]. Cancer Communications, 2020, 40(11): 564-585.
[45] CABEZAS-CAMARERO S, PÉREZ-SEGURA P. Liquid Biopsy in Head and Neck Cancer: Current Evidence and Future Perspective on Squamous Cell, Salivary Gland, Paranasal Sinus and Nasopharyngeal Cancers[J/OL]. Cancers, 2022, 14(12): 2858.
[46] GHIMIRE B, et al. Use of circulating tumour DNA in nasopharyngeal carcinoma to detect minimal residual disease[J/OL]. BMJ Case Reports, 2022, 15(6): e251196.
[47] YOU R, et al. Relationship of circulating tumor cells and Epstein–Barr virus DNA to progression‐free survival and overall survival in metastatic nasopharyngeal carcinoma patients[J/OL]. International Journal of Cancer, 2019, 145(10): 2873-2883.
[48] MÖHRMANN L, et al. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers[J/OL]. Clinical Cancer Research, 2018, 24(1): 181-188.
[49] SKOG J, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers[J/OL]. Nature Cell Biology, 2008, 10(12): 1470-1476.
[50] KRUG A K, et al. Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma[J/OL]. Annals of Oncology, 2018, 29(3): 700-706.
[51] LIU Y, WEN J, HUANG W. Exosomes in nasopharyngeal carcinoma[J/OL]. Clinica Chimica Acta, 2021, 523: 355-364.
[52] SABOUR S, GHAJARI H. Diagnostic value of exosomal CIRCMYC in radioresistant nasopharyngeal carcinoma: Methodological issues[J/OL]. Head & Neck, 2021, 43(5): 1690-1690.
[53] LU J, et al. Predictive value of miR-9 as a potential biomarker for nasopharyngeal carcinoma metastasis[J/OL]. British Journal of Cancer, 2014, 110(2): 392-398.
[54] YANG W, et al. Exosomal miR-205-5p enhances angiogenesis and nasopharyngeal carcinoma metastasis by targeting desmocollin-2[J/OL]. Molecular Therapy - Oncolytics, 2022, 24: 612-623.
[55] CARTHEW R W, SONTHEIMER E J. Origins and Mechanisms of miRNAs and siRNAs[J/OL]. Cell, 2009, 136(4): 642-655.
[56] CATALANOTTO C, COGONI C, ZARDO G. MicroRNA in Control of Gene Expression: An Overview of Nuclear Functions[J/OL]. International Journal of Molecular Sciences, 2016, 17(10): 1712.
[57] ZEDAN A H, et al. Circulating miRNAs in localized/locally advanced prostate cancer patients after radical prostatectomy and radiotherapy[J/OL]. The Prostate, 2019, 79(4): 425-432.
[58] NG E K O, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening[J/OL]. Gut, 2009, 58(10): 1375-1381.
[59] GIUSSANI M, et al. Circulating miRNAs as Novel Non-Invasive Biomarkers to Aid the Early Diagnosis of Suspicious Breast Lesions for Which Biopsy Is Recommended[J/OL]. Cancers, 2021, 13(16): 4028.
[60] MIYOSHI J, et al. A microRNA-based liquid biopsy signature for the early detection of esophageal squamous cell carcinoma: a retrospective, prospective and multicenter study[J/OL]. Molecular Cancer, 2022, 21(1): 44.
[61] WEN W, et al. Identification of two microRNA signatures in whole blood as novel biomarkers for diagnosis of nasopharyngeal carcinoma[J/OL]. Journal of Translational Medicine, 2019, 17(1): 186.
[62] ZHENG X H, et al. Plasma microRNA profiles of nasopharyngeal carcinoma patients reveal miR-548q and miR-483-5p as potential biomarkers[J/OL]. Chinese Journal of Cancer, 2014[2023-09-23].
http://www.cjcsysu.cn/abstract_AOP.asp?fr=doi&id=13-246.
[63] LIU N, et al. A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma: Serum miRNA predicts survival in NPC[J/OL]. International Journal of Cancer, 2014, 134(6): 1359-1368.
[64] ZHANG H, et al. Identification of a 7‐microRNA signature in plasma as promising biomarker for nasopharyngeal carcinoma detection[J/OL]. Cancer Medicine, 2020, 9(3): 1230-1241.
[65] WU L, et al. Genome-wide study of salivary microRNAs as potential noninvasive biomarkers for detection of nasopharyngeal carcinoma[J/OL]. BMC Cancer, 2019, 19(1): 843.